Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04020198 · ClinicalTrials.gov registry record
A Pilot Biomarker Study Assessing Alpha-synuclein Aggregates Across Biofluid Reservoirs in Patients With Synucleinopathies
A clinical trial, sponsored by Stony Brook University.
- Terminated
- Registry status
- 8
- Enrollment target
NCT04020198 is a clinical trial that was terminated before completion, run by Stony Brook University. The registered enrollment target is 8 participants.
The verdict
NCT04020198 was terminated before completion, sponsored by Stony Brook University.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
This will be an observational study looking at clinical and biomarker characteristics in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Rapid Eye Movement Sleep Behavior Disorder (RBD), Normal Pressure Hydrocephalus and matched controls. Saliva, plasma, serum, urine, and cerebrospinal fluid (CSF) samples will be collected from participants.
Interventions
- OTHER Biomarker assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-01-15 |
| Est. Completion | 2022-10-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04020198
The ClinicalTrials.gov registry entry for NCT04020198 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Biomarker assay is the first listed.
NCT04020198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04020198 about?
NCT04020198 is a clinical study titled "A Pilot Biomarker Study Assessing Alpha-synuclein Aggregates Across Biofluid Reservoirs in Patients With Synucleinopathies". This will be an observational study looking at clinical and biomarker characteristics in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Rapid Eye Movement Sleep Behavior Disorder (RBD), Normal Pressure Hydrocephalus and matched controls. Saliva, plasma, serum, urine, and cere...
What is the current status of trial NCT04020198?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2020-01-15. Estimated completion is 2022-10-19.
What interventions are being tested in trial NCT04020198?
The interventions under investigation include: Biomarker assay (OTHER).
Who is sponsoring clinical trial NCT04020198?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.